Clinical Trials Browser

Interventional × Breast Neoplasms × sacituzumab govitecan × Clear all

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

Breast Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07178730 2026-05-06

ADAPT-TN-IV

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05143229 2026-05-01

ASSET

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Phase 2 Active not recruiting

Breast Neoplasms

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Phase 3 Active not recruiting

Breast Neoplasms

NCT07367178 2026-01-28

SATROPIN

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07368543 2026-01-28

STORM

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast Neoplasms

NCT06263543 2025-12-26

SERIES

Phase 2 Recruiting

Breast Neoplasms

NCT07299409 2025-12-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

Phase 2 Recruiting

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

Breast Neoplasms

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms, Meningeal Carcinomatosis

NCT07163481 2025-09-16

SoGreat

Phase 1 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2 Recruiting

Breast Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

543 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT06236269 2024-07-19

ACROSS-TROP2

Phase 2 Recruiting

Breast Neoplasms

NCT06462079 2024-06-17

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Breast Neoplasms

NCT06328387 2024-03-25

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT02574455 2022-06-15

ASCENT

Phase 3 Completed

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 1 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms